Dennis M Klinman

This inventor holds 54 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 8 EPO patents, primarily in CpG Oligonucleotides (CPC class A61K). Top assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, University of Iowa Research Foundation, Coley Pharmaceutical Group, Inc.. Active years: 2001-2018.

USPTO Granted Patents = 54 (Patent Applications = 1)

% Patents Active = 42.6

CIPO Patents = 2

EPO Patents = 8 (Patent Applications = 6)

Average Co-Inventor Count = 3.1

ph-index = 19

Forward Citations = 1,518(Granted Patents)

Forward Citations (Not Self Cited) = 1,161(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

51 out of 3,690

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

13 out of 925

University of Iowa Research Foundation

patents

12 out of 41

Coley Pharmaceutical Group, Inc.

The University of Tennessee Research Foundation

patents

6. 1 out of 2

Uniformed Services University of the Health Sciences, an Institution of Higher Learning Within the Department of Defense

patents

7. 3 out of 834,436

Other

patents

where one patent can have more than one assignee

Years Active: 2001-2018

Loading Chart...

Areas of Expertise:

CpG Oligonucleotides

Cancer Treatment

Immune Response

Wound Healing

Biodegradable Polymers

Immunostimulatory Molecules

Inflammatory Diseases

Oligodeoxynucleotides

Immunological Adjuvants

Polynucleotide Compositions

Angiogenesis

Dendritic Cells

54 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10076535 - Use of CPG oligonucleotides co-formulated with an antibiotic to accelerate wound healing (2018-09-18),

2. 9919058 - Polyketal particles including a CpG oligodeoxynucleotide for the treatment of lung cancer (2018-03-20),

3. 9163244 - Suppressors of CpG oligonucleotides and methods of use (2015-10-20),

4. 9107813 - Immunogenic compositions containing anthrax antigen, biodegradable polymer microparticles, and polynucleotide-containing immunological adjuvant (2015-08-18),

5. 9006203 - Method of reducing inflammatory infiltration in subjects with inflammatory lung disease (2015-04-14),

6. 8895521 - Methods and compositions for the treatment of uveitis (2014-11-25),

7. 8741869 - Oligodeoxynucleotide and its use to induce an immune response (2014-06-03),

8. 8697666 - Anti-cancer oligodeoxynucleotides (2014-04-15),

9. 8685416 - Compositions and methods for the treatment of cancer (2014-04-01),

10. 8580944 - Suppressors of CpG oligonucleotides and methods of use (2013-11-12),

11. 8557789 - Method of treating inflammatory arthropathies with supressors of CPG oligonucleotides (2013-10-15),

12. 8501188 - Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides (2013-08-06),

13. 8481055 - Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides (2013-07-09),

14. 8470342 - Methods of altering an immune response induced by CpG oligodeoxynucleotides (2013-06-25),

15. 8466116 - Use of CpG oligodeoxynucleotides to induce epithelial cell growth (2013-06-18),

Title: Dennis M Klinman - Pioneering Innovator in Biomedical Technologies

Introduction:

Dennis M Klinman, a remarkable inventor based in Potomac, MD (US), has made significant contributions to the world of biomedical technology. With an impressive portfolio of 54 patents, Klinman continues to drive advancements in healthcare and pharmaceuticals.

Latest Patents:

1. "Use of CPG oligonucleotides co-formulated with an antibiotic to accelerate wound healing": This patent highlights Klinman's innovative approach to enhancing wound healing by combining antibiotics with ingredients that promote healing without compromising antibacterial properties.

2. "Polyketal particles including a CpG oligodeoxynucleotide for the treatment of lung cancer": This patent showcases Klinman's novel method for treating lung cancer using polyketal particles containing a CpG oligodeoxynucleotide.

Career Highlights:

Throughout his career, Klinman has worked with prestigious organizations such as The United States of America As Represented by the Department of Health and Human Services and The United States of America As Represented by the Secretary of the Department of Health and Human Services. His groundbreaking research has paved the way for advancements in healthcare that benefit society as a whole.

Collaborations:

Klinman has collaborated with esteemed colleagues, including Daniela Verthelyi and Arthur Mertz Krieg, to further his research in biomedical technologies. These partnerships have led to groundbreaking discoveries and innovative solutions in the field of healthcare.

Conclusion:

In conclusion, Dennis M Klinman stands as a beacon of inspiration in the world of biomedical inventions, with a legacy that continues to shape the future of healthcare and pharmaceuticals. His dedication to innovation and collaboration underscores his commitment to improving human health and well-being through pioneering technologies.